VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, ...
A study, published in Molecular Psychiatry, led by Prof. Bernard Lerer from the Department of Psychiatry at the Hadassah—Hebrew University Medical Center shows promising results for using psilocybin, ...
The approval to initiate this Phase 2 clinical trial represents a pivotal moment in the clinical development of Optimi's GMP natural psilocybin extract capsules. Building on its established status as ...
Toronto, Ontario--(Newsfile Corp. - June 7, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), a company engaged in the production, growth, and sale of ...
The Trump administration is set to weigh in on whether the hallucinogenic compound psilocybin should be moved into a less restrictive class of drugs under federal regulations. Regulation of psilocybin ...
As many states and municipalities around the country grapple with the ever-increasing popularity of psilocybin-based products, a few have staked out leading positions in what may be the next wave of ...
Colorado could limit the state’s emerging magic mushroom industry to one strain and severely restrict the use of psilocybin extractions, according to the final draft of proposed natural medicine ...
Share on Pinterest A new study compared psilocybin with a common SSRI and found that both drugs improved symptoms, while psilocybin provided added benefits. Maki Nakamura/Getty Images A new study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results